Quarterly ResultAug 6, 2026, 07:02 AM
Sotera Health Q2 Revenue +9.2%, EPS $0.19; Raises FY26 Outlook
AI Summary
Sotera Health Company announced strong financial results for Q2 2026, with net revenues increasing 9.2% and net income rising significantly to $54 million. The company also reported a 10.0% increase in Adjusted EBITDA and a 30% rise in Adjusted EPS. Following this strong performance, Sotera Health raised its full-year 2026 outlook for both net revenues and Adjusted EBITDA growth, reflecting confidence in continued execution across its business units.
Key Highlights
- Q2 2026 net revenues increased 9.2% to $321.4 million (8.0% constant currency) compared to Q2 2025.
- Q2 2026 net income was $54 million, or $0.19 per diluted share, up from $8 million or $0.03 in Q2 2025.
- Q2 2026 Adjusted EBITDA increased 10.0% (8.7% constant currency) to $165.7 million.
- Q2 2026 Adjusted EPS was $0.26, a 30% increase per diluted share.
- Full-year 2026 net revenues growth outlook raised to 5.25%-6.75% on a constant currency basis.
- Full-year 2026 Adjusted EBITDA growth outlook raised to 5.75%-7.25% on a constant currency basis.
- Sterigenics segment revenue grew 7.0% constant currency; Nordion 16.7%; Nelson Labs 5.4%.
- Net Leverage Ratio improved to 3.0x, achieving the long-term target range.
Price Impact
More from SHC